Activity of cabozantinib (cabo) after PD-1/PD-L1 immune checkpoint blockade (ICB) in metastatic clear cell renal cell carcinoma (mccRCC - McGregor, B A; Lalani, A-K; Xie, W (Ann Oncol, 2018)